Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v4-FR
Language French French
Date Updated 2019-11-26 2019-11-26
Drug Identification Number 02279479 02279479
Brand name APIDRA APIDRA
Common or Proper name Apidra Apidra
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients INSULIN GLULISINE INSULIN GLULISINE
Strength(s) 100UNIT 100UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 1 1
ATC code A10AB A10AB
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2020-01-15 2020-01-15
Estimated end date 2020-02-10 2020-02-10
Actual end date 2019-11-26 2019-11-26
Shortage status Avoided shortage Avoided shortage
Company comments Production Delay - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Production Delay - The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments